Skip to main content

Eli Lilly and Company (LLY) Stock

Eli Lilly and Company Stock Details, Movements and Public Alerts

Stock Details

Eli Lilly and Company (LLY), a prominent company in the life sciences sector within the pharmaceutical preparations industry, is based in USA and primarily trades on the NYSE.Currently, the stock is trading at $772.56. Over the past 52 weeks, it has ranged between $675.71 and $967.27. This places the current price at 79.9% of its 52-week high and 14.3% above its 52-week low. Recent trading volume was recorded at 320,855. The International Securities Identification Number (ISIN) for this stock is US5324571083. There are currently 3 active alerts set for LLY by users.

Market Cap

$696.15B

52-Week High

$967.27

-20.13% from high

52-Week Low

$675.71

+14.33% from low

Avg Daily Volume

320,855

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

63.30

Above market average

Forward P/E

35.59

Earnings expected to grow

PEG Ratio

1.19

Reasonably valued

Price to Book

44.16

EV/EBITDA

44.95

EPS (TTM)

$12.25

Price to Sales

14.21

Beta

0.39

Less volatile than market

How is LLY valued relative to its earnings and growth?
Eli Lilly and Company trades at a P/E ratio of 63.30, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 35.59 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 1.19 indicates reasonable value when growth is considered.
What is LLY's risk profile compared to the market?
With a beta of 0.39, Eli Lilly and Company is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 44.16 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

22.70%

Operating Margin

42.50%

Return on Equity

77.30%

Return on Assets

16.50%

Revenue Growth (YoY)

45.20%

Earnings Growth (YoY)

23.40%

How profitable and efficient is LLY's business model?
Eli Lilly and Company achieves a profit margin of 22.70%, meaning it retains $22.70 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 42.50% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 77.30% and ROA at 16.50%, the company generates strong returns on invested capital.
What are LLY's recent growth trends?
Eli Lilly and Company's revenue grew by 45.20% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. Earnings increased by 23.40% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against PHARMACEUTICAL PREPARATIONS industry averages for proper context.

Dividend Information

Dividend Per Share

$5.40

Dividend Yield

0.77%

Ex-Dividend Date

8/15/2025

Dividend Date

9/10/2025

What dividend income can investors expect from LLY?
Eli Lilly and Company offers a dividend yield of 0.77%, paying $5.40 per share annually. This modest yield below 2% suggests the company prioritizes growth investments over current income. While the dividend provides some return, investors are likely attracted more by capital appreciation potential than income generation. To receive the next dividend, shares must be purchased before the ex-dividend date of 8/15/2025.
How reliable is LLY's dividend for long-term investors?
The dividend sustainability can be assessed through the payout ratio - Eli Lilly and Company pays $5.40 per share in dividends against earnings of $12.25 per share, resulting in a payout ratio of 44.08%. This balanced payout between 30-60% suggests a sustainable dividend policy that allows both shareholder returns and business reinvestment. The dividend appears well-covered by earnings. The next dividend payment is scheduled for 9/10/2025.

Company Size & Market

Shares Outstanding

897.74M

Book Value/Share

$16.64

Asset Type

Common Stock

What is LLY's market capitalization and position?
Eli Lilly and Company has a market capitalization of $696.15B, classifying it as a mega-cap stock (over $200B). These are the largest, most established companies globally, typically offering stability and liquidity but with more modest growth potential. Mega-caps often pay dividends and weather economic downturns better than smaller companies. With 897.74M shares outstanding, the company's ownership is relatively concentrated. As a major player in the PHARMACEUTICAL PREPARATIONS industry, it competes with other firms in this sector.
How does LLY's price compare to its book value?
Eli Lilly and Company's book value per share is $16.64, while the current stock price is $772.56, resulting in a price-to-book (P/B) ratio of 46.43. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$951.98

23.22% upside potential

Analyst Recommendations

Strong Buy

6

Buy

16

Hold

5

Sell

1

Strong Sell

0

How reliable are analyst predictions for LLY?
28 analysts cover LLY with 79% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $951.98 implies 23.2% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on LLY?
Current analyst recommendations:6 Strong Buy, 16 Buy, 5 Hold, 1 Sell, 0The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 1, 2025, 02:35 AM

Technical Indicators

What does LLY's RSI value tell investors?
RSI data is not available for this stock.
How should traders interpret LLY's MACD and moving average crossovers?
MACD and moving average data are not available for this stock.

No technical indicators available yet.

Active Alerts

Alert Condition
Volume change
Threshold
50%
Created
Jul 17, 2025, 01:08 PM
Alert Condition
Forward P/E falls below
Threshold
35x
Created
Jul 17, 2025, 12:22 PM
Alert Condition
Price falls below
Threshold
$700.00
Created
Jul 17, 2025, 06:15 AM

Stay Ahead of the Market with Eli Lilly and Company Alerts

Set up price alerts for Eli Lilly and Company and get notified instantly when the price hits your target. Never miss an important price movement again.